2025. IN SILICO STUDY OF VANILLIN SCHIFF BASES AS PROTO ONCOGENE TYROSINE KINASE INHIBITORS OF CHRONIC MYELOID LEUKEMIA. Frontier in Medical and Health Research. 3, 10 (Dec. 2025), 570–577.